Hasan Slika
Epac as a tractable therapeutic target
Slika, Hasan; Mansour, Hadi; Nasser, Suzanne; Shaito, Abdullah; Kobeissy, Firas; N. Orekhov, Alexander; Pintus, Gianfranco; Eid, Ali
Authors
Hadi Mansour
Suzanne Nasser s.n.nasser@keele.ac.uk
Abdullah Shaito
Firas Kobeissy
Alexander N. Orekhov
Gianfranco Pintus
Ali Eid
Abstract
In 1957, cyclic adenosine monophosphate (cAMP) was identified as the first secondary messenger, and the first signaling cascade discovered was the cAMP-protein kinase A (PKA) pathway. Since then, cAMP has received increasing attention given its multitude of actions. Not long ago, a new cAMP effector named exchange protein directly activated by cAMP (Epac) emerged as a critical mediator of cAMP's actions. Epac mediates a plethora of pathophysiologic processes and contributes to the pathogenesis of several diseases such as cancer, cardiovascular disease, diabetes, lung fibrosis, neurological disorders, and others. These findings strongly underscore the potential of Epac as a tractable therapeutic target. In this context, Epac modulators seem to possess unique characteristics and advantages and hold the promise of providing more efficacious treatments for a wide array of diseases. This paper provides an in-depth dissection and analysis of Epac structure, distribution, subcellular compartmentalization, and signaling mechanisms. We elaborate on how these characteristics can be utilized to design specific, efficient, and safe Epac agonists and antagonists that can be incorporated into future pharmacotherapeutics. In addition, we provide a detailed portfolio for specific Epac modulators highlighting their discovery, advantages, potential concerns, and utilization in the context of clinical disease entities.
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 6, 2023 |
Publication Date | 2023-04 |
Publicly Available Date | May 30, 2023 |
Journal | European Journal of Pharmacology |
Print ISSN | 0014-2999 |
Electronic ISSN | 1879-0712 |
Publisher | Elsevier |
Volume | 945 |
Article Number | 175645 |
DOI | https://doi.org/10.1016/j.ejphar.2023.175645 |
Keywords | cAMP, Epac; Cancer; Cardiovascular disease; Pharmacotherapeutics |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0014299923001565?via%3Dihub |
Files
1-s2.0-S0014299923001565-main.pdf
(4.7 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Inflammation and hypertension: Underlying mechanisms and emerging understandings.
(2023)
Journal Article
Origanum syriacum L. Attenuates the Malignant Phenotype of MDA-MB231 Breast Cancer Cells
(2022)
Journal Article
Mechanisms underlying the effects of caloric restriction on hypertension
(2022)
Journal Article
Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms
(2022)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search